5 Longevity Startups Quietly Changing How We Think About Getting Old
Skip past the usual Altos-and-Retro roundup. These five are solving the unglamorous problems that actually decide whether any of this reaches your medicine cabinet.
If you’ve read this site’s other roundups of cutting-edge longevity startups or the biotech rebels rewriting aging, you already know the household names: Altos, Retro, Insilico, Calico. Deep-pocketed, well-covered, worth watching. This isn’t that list. 🧬 The five companies below are working on the less glamorous half of the problem: how you actually get a longevity drug through a regulator, where you find a genuinely new drug target instead of recycling the same three pathways, and how you manufacture cell therapy at a price that isn’t reserved for billionaires. Different problem, same stakes.
Loyal is answering to the FDA right now, not someday
Every other company on every “longevity startup” list talks about human trials as a distant horizon. Loyal skipped that argument entirely by going to dogs first. Its lead drug, LOY-002, targets excess IGF-1 in senior dogs, and the FDA’s Center for Veterinary Medicine has already accepted both the safety and efficacy sections of its conditional approval application. That’s two of three required technical sections cleared, with manufacturing review the last hurdle before Loyal can apply for Expanded Conditional Approval. 🐕
Why this matters beyond dog owners:
It’s the first time any regulator anywhere has formally treated aging itself, not a specific disease, as something a drug can target
The pivotal STAY study enrolled 1,300 dogs across 70 clinics, the largest veterinary clinical trial ever run
Dogs share our homes, our food, and a decent chunk of our genome, making them a far more relevant proxy than lab mice
A successful approval creates the regulatory playbook that human longevity drugs will eventually have to follow
Founder Celine Halioua started the company in 2019 specifically to build that playbook, and a launch, expected before the end of 2026, would be the first FDA-recognized lifespan extension drug for any species. Any species. Have you looked at your own dog and wondered whether a decade of extra good years is actually within reach before it is for you? 🚀
Fauna Bio is mining hibernating squirrels for human drug targets
Most drug discovery starts with human tissue and hopes for the best. Fauna Bio starts somewhere weirder: the 13-lined ground squirrel, an animal that can drop its metabolic rate to 1 to 3% of normal for months, rewarm its organs from near-freezing without stroke damage, and rebuild muscle after lying motionless all winter. The company’s Convergence platform compares gene activity in squirrels (and more than 50 other extreme-survival species) against human disease data to spot targets evolution has already stress-tested. ⚡
Its first drug candidate, Faun1083, targets heart failure with preserved ejection fraction and is headed into human trials in 2026
Eli Lilly signed a deal worth up to $494 million in milestones to use the platform for obesity targets
Novo Nordisk has a separate collaboration exploring the same hibernation biology
NASA is funding Fauna’s work on whether torpor-like states could protect astronauts from radiation on long missions
CEO Ashley Zehnder puts the logic simply: evolution already ran the world’s longest, most rigorous drug discovery experiment, so why not read the results instead of starting from scratch. 🔬
Gero treats aging as a physics problem instead of a biology one
Where most AI longevity companies hunt for molecular targets, Gero built its platform on a different premise entirely: that aging follows mathematical laws closer to statistical physics than to conventional biology. The Singapore- and San Francisco-based company trained AI models on roughly 10 million longitudinal medical records to separate reversible disease symptoms from the deeper, slow-moving processes of aging itself, hunting for “hub” targets that touch multiple chronic diseases at once. 💡
Gero was named a 2026 World Economic Forum Technology Pioneer for the approach
A 2025 collaboration with Chugai Pharmaceutical, part of the Roche Group, is worth up to $250 million in milestones plus royalties
The company previously ran a research partnership with Pfizer
Its generative model, ProtoBind-Diff, designs small molecules directly from a target protein’s sequence
Whether “gerophysics” turns out to be a genuinely different lens or just a rebrand of systems biology is still an open question. But a major pharma partner betting quarter-billion-dollar milestones on it is a signal worth noticing.
Cellino is trying to fix the boring problem nobody wants to fund
Stem cell therapy has a dirty secret: making the cells is still mostly manual labor. A trained scientist sits at a bench, looks at cells under a microscope, and picks out the bad ones with a pipette. That doesn’t scale past a handful of patients, and it’s a big reason cell therapies remain wildly expensive. Cellino is automating that entire process with AI-guided lasers that identify and remove unwanted cells inside a closed, cassette-based system, aiming to manufacture patient-specific stem cells the way a semiconductor fab manufactures chips. 🛠️
The company has raised roughly $125 million, including an $80 million round led by Bayer’s investment arm
It won $25 million from ARPA-H to build an autonomous “cell foundry”
It’s collaborating with the NIH on the first autologous iPSC-derived clinical trial in the U.S.
It landed on Fast Company‘s 2026 list of the world’s most innovative companies
None of this shows up in flashy “we reversed aging in mice” headlines, which is exactly why it gets overlooked. But if cell therapy ever becomes something more than a boutique option for the wealthy, it’s because someone solved manufacturing, not because someone found one more gene to reprogram.
Rubedo Life Sciences is going after one specific kind of zombie cell
Senolytics, the drugs meant to clear out aging “zombie” cells, have mostly been a blunt instrument so far. Rubedo Life Sciences is trying to make the approach precise instead. Its lead candidate, RLS-1496, selectively modulates GPX4, a protein that leaves pathological senescent cells specifically vulnerable to a form of cell death called ferroptosis, in theory sparing healthy tissue that a blunter drug would also damage. 🧪
The FDA cleared its IND application in September 2025 for a Phase 1b/2a trial in actinic keratosis, a common precancerous skin condition
A separate EMA-cleared trial is running in psoriasis, atopic dermatitis, and photoaged skin
The company closed a $40 million Series A backed by Khosla Ventures
Skin conditions are the current focus, but the same mechanism is being explored for metabolic disease and sarcopenia
Starting with dermatology instead of “cure aging” isn’t a lack of ambition. It’s a company picking a fast, well-defined regulatory path first and saving the bigger claims for after they’ve proven the mechanism works in humans.
What actually separates these five
None of these five are locks. Loyal could still stumble on manufacturing review. Cellino’s approach might not scale as cleanly as the semiconductor analogy suggests. What connects them isn’t a shared mechanism, it’s a shared instinct: pick the fastest honest path to human data, whether that’s a dog, a squirrel genome, a physics model, a factory floor, or a skin condition instead of the whole aging process at once.
Loyal: regulatory pathway, first mover with an actual FDA-facing timeline
Fauna Bio: discovery platform, new targets from animals instead of recycled human biology
Gero: computational approach, physics-first modeling backed by major pharma money
Cellino: infrastructure, solving the manufacturing bottleneck nobody else wants to touch
Rubedo: precision therapeutics, narrowing senolytics down to one well-defined mechanism
If you had to bet on which of these actually changes clinical practice first, would you put your money on the one closest to approval, or the one with the biggest scientific swing?